噻托溴铵联合沙美特罗/氟替卡松吸入治疗慢性阻塞性肺疾病疗效观察

摘要

Objective To evaluate the effect of inhaled sameterol/fluticasone and tiotropium bromide in treatment of chronic obstructive pulmonary disease (COPD). Methods 76 patients with COPD who had received same treatments were randomly divided into two groups with 38 patients in each group. Sameterol/fluticasone group (compared group) received inhaled sameterol/fluticasone, sameterol/fluticasone and tiotropium bromide group (treatment group) received inhaled sameterol/fluticasone and tiotropium bromide. The changes of symptom, lung function and blood gas were observed for three months in each group. Results 36 patients of each group finished the therapy. At the end of therapy,the situation of patients in each group was better than that before treatment. But the differences of value of FEV1/predictive and value of FEV1/FVC between two groups were different (P < 0. 01) ,the differences of PaO2 and PaC02 between two groups were different too. Conclusion The treatment of amlmeterol/fluticasone plus tiotropium bromide inhalation is safe and effective for the treatment of COPD.%目的 探讨噻托溴铵联合沙美特罗/氟替卡松吸入治疗对慢性阻塞性肺疾病(COPD)的疗效.方法 76例COPD随机分为两组,对照组吸入沙美特罗/氟替卡松,观察组吸入沙美特罗/氟替卡松和噻托溴铵,其他治疗一致.3个月后比较两组治疗前后症状、FEV1(第1秒呼气量)/预计值和FEV1/FVC(用力肺活量)及血气变化.结果 两组各有36例完成治疗.治疗前两组之间各项指标无显著差异,治疗后两组自觉症状改善明显,FEV1/预计值和FEV1/FVC差异明显(P＜0.01),PaO2显著升高(P＜0.01),PaCO2降低(P＜0.05).结论 噻托溴铵联合沙美特罗/氟替卡松吸入是治疗COPD的安全有效方法.